Stock Price & Analysis

Based on the provided data, here's a concise analysis for MetLife (MET) stock:

Technical Analysis The stock is currently trading at $85.76, down 1.29% in the regular market session with moderate volume of 3.6M shares. The RSI(14) at 59.17 indicates neutral momentum, while the MACD at 0.86 suggests a slightly bullish trend.

Analyst Sentiment Recent analyst ratings are notably bullish:

• JPMorgan (Jan 7, 2025): Maintains Buy, PT raised to $88 from $86
• Barclays (Jan 6, 2025): Maintains Buy, PT raised to $96 from $90
• TD Cowen (Nov 27, 2024): Maintains Strong Buy, PT raised to $99 from $97

Recent Developments MetLife recently announced the acquisition of three portfolio management teams from Mesirow, which will enhance its institutional asset management business. This transaction involves approximately $6 billion in assets and includes about 20 investment professionals.

Upcoming Catalyst The company is scheduled to report Q4 2024 earnings on January 29, 2025. Analysts expect EPS of $2.17, representing a 12.4% increase year-over-year.

Recommendation Based on current technical indicators and strong analyst support, MET stock appears to be a moderate buy at current levels. The stock is trading near its 20-day SMA of $83.04, suggesting a potential support level. Multiple analysts maintain bullish ratings with price targets indicating 7-17% upside potential.

Based on the provided data and market analysis, here's the price prediction for MetLife (MET) stock in 2025:

MetLife stock is projected to reach $93.54 by mid-2025, representing a potential upside of 13.9% from current levels, driven by the company's successful implementation of its Frontier Growth strategy and strong Q4 2024 earnings expectations. The stock is currently trading at $85.76, showing technical support at the Fibonacci level of $83.98.

The positive outlook is supported by MetLife's recent acquisition of three portfolio management teams from Mesirow, which will enhance its institutional asset management business with approximately $6 billion in additional assets. This strategic move, combined with analysts' expectations of $8.22 EPS for fiscal 2024, positions the company for continued growth.

The S1 support level for MET Stock is $81.05 ,The R1 resistant level for MET Stock is $87.43.

As of the end of day on 2025-01-24, the price of MET Stock was $86.03.

The target price for MET Stock according to analyst rating is 97.40, with the highest price target at 104.00 and the lowest at 88.00. Analysts have a Strong Buy rating on MET Stock overall.

The market cap of MET is $59.6B.

Based on the provided data, here's a comprehensive analysis of MetLife's (MET) valuation:

Valuation Analysis MetLife shows improving profitability with Q3 2024 net income reaching $1.275 billion, up significantly from $800 million in Q1 2024. The PE ratio has decreased from 25.64x in Q1 to 16.71x in Q3 2024, suggesting improving valuation metrics.

Financial Performance

• Revenue growth remains strong, increasing from $16.03B in Q1 to $18.50B in Q3 2024
• ROE improved significantly from 7.13% to 12.60% over the same period
• Net margin expanded from 5.46% to 7.25%, indicating improved operational efficiency

Analyst Sentiment Recent analyst actions are predominantly positive:

• JPMorgan raised target to $88 with an Overweight rating
• Barclays increased target to $96, maintaining Overweight rating
• TD Cowen raised target to $99 with a Buy rating

Technical Analysis The stock currently shows moderate RSI of 59.17, indicating neither overbought nor oversold conditions. The stock is trading above both its 20-day (83.04) and 60-day (82.96) moving averages, suggesting positive momentum.

Conclusion Based on the comprehensive analysis, MetLife is NOT overvalued. The company demonstrates strong financial performance, improving profitability metrics, and positive analyst sentiment. The current PE ratio of 16.71x is reasonable for the insurance sector, especially considering the company's improving ROE and margins. The technical indicators also support this conclusion, showing healthy momentum without excessive valuation.

MetLife, Inc. is a financial services company. The Company is engaged in providing insurance, annuities, employee benefits and asset management for individual and institutional customers. The Company operates through six segments: Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its Group Benefits segment offers life insurance, dental, group short- and long-term disability, individual disability, accidental death and dismemberment (AD&D) insurance, vision, and accident and health insurance, as well as prepaid legal plans and pet insurance. It also sells administrative services-only (ASO) arrangements to some employers. Its RIS segment provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products.

Based on the provided data and market analysis, here is the price prediction for MetLife (MET) stock by 2030:

MetLife stock is projected to reach $145-155 by 2030, driven by its ambitious 5-year Frontier Growth strategy targeting $25 billion in free cash flow generation and strong analyst consensus. The company's recent acquisition of three portfolio management teams and $6 billion in assets demonstrates strategic expansion in institutional asset management. The stock's current valuation at 23.5x forward earnings with projected 14% earnings growth provides room for sustained long-term appreciation.

MET has a total of 45000 employees.